UK HealthTech firm Medopad, which has raised $28m, is expanding to the US with the acquisition of Sherbit, a Silicon Valley startup leveraging AI to improve chronic disease patient care.
Medopad’s proprietary technology connects patients with healthcare professionals, enabling them to analyse a patient’s data and detect medical conditions.
The scaleup is already working with Royal Free London, Guy’s and St Thomas’, Bart’s, and Chelsea & Westminster hospitals in the UK. Medopad is also working on projects in countries including China, Germany and Singapore.
Medopad CEO and founder Dan Vahdat said: “At Medopad we want to create a world where people can live longer. We are working with some of the biggest companies in the world to improve the way doctors care for their patients by monitoring them at home and spotting any complications before they arise.
“We are expanding rapidly across the world and acquiring Sherbit is just the first step for us in the US.
“Sherbit has a strong track record of success working with some of the most prestigious healthcare organisations in the US, including the Mayo Clinic, Tufts Medical Center and Jefferson Health. Through this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions.”
US and Asian investment in UK tech skyrockets
Sherbit CEO Alex Senemar said: “Sherbit and Medopad have the same vision to help people be healthier and live longer. We’re excited to leverage Medopad’s technology, clinical, and predictive analytics capabilities to expand what’s possible for our customers.”
The terms of the acquisition have not been disclosed.
Sherbit raised an undisclosed venture round in October 2016 from Plug and Play and Harvard Medical School.